<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373371</url>
  </required_header>
  <id_info>
    <org_study_id>I14034</org_study_id>
    <nct_id>NCT02373371</nct_id>
  </id_info>
  <brief_title>Actinic Keratoses Treatment With Metvix® in Combination With Light</brief_title>
  <official_title>Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare efficacy and safety of Metvix® natural
      daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy in
      subjects with mild actinic keratoses (intra-individual comparison)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2015</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The number of lesions is assessed at baseline (before treatment) and 12 weeks later.
The difference in lesions is recorded for each patient. The mean of disappeared lesions are then calculated for all patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Assesment</measure>
    <time_frame>at inclusion (after treatment)</time_frame>
    <description>Pain assesment with a VAS Pain scale
Visual analog scale [VAS] is a continuous scale comprised of a horizontal scale of 10 cm length . The scale is anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesions Disappearance Rate at 1 Months From Baseline.</measure>
    <time_frame>0(baseline),1 month</time_frame>
    <description>The number of lesions is assessed at baseline (before treatment) and 1 month later.
The difference in lesions is recorded for each patient. The rate is the quotient: &quot; difference in lesions between baseline and at 1 month &quot;/nubmer of lesions at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesions Disappearance Rate at 6 Months From Baseline.</measure>
    <time_frame>0(baseline), 6 month</time_frame>
    <description>The number of lesions is assessed at baseline (before treatment) and 6 month later.
The difference in lesions is recorded for each patient. The rate is the quotient: &quot; difference in lesions between baseline and at 6 month &quot;/nubmer of lesions at baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Daylight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metvix®</intervention_name>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_label>Daylight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic Therapy Blue light</intervention_name>
    <description>Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic Therapy Daylight</intervention_name>
    <description>Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
    <arm_group_label>Daylight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female above 18 years;

          -  Subject with clinical diagnosis of mild Actinic Keratosis (AK) on the face or the
             scalp with or without clinical diagnosis of moderate AK on the target areas (TAs);

        Exclusion Criteria:

          -  Subject with clinical diagnosis of at least one severe AK on TAs

          -  Subject with clinical diagnosis of other skin disease (including non-melanoma skin
             cancer) on the TAs;

          -  Subject with pigmented AK on the TAs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <results_first_submitted>January 9, 2019</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2019</results_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daylight</title>
          <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
Metvix®
Photodynamic Therapy Daylight: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
        </group>
        <group group_id="P2">
          <title>Conventional Treatment</title>
          <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
Metvix®
Photodynamic Therapy Blue light: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daylight</title>
          <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
Metvix®
Photodynamic Therapy Daylight: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
        </group>
        <group group_id="B2">
          <title>Conventional Treatment</title>
          <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
Metvix®
Photodynamic Therapy Blue light: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.0" lower_limit="67.0" upper_limit="83.0"/>
                    <measurement group_id="B2" value="75.0" lower_limit="67.0" upper_limit="83.0"/>
                    <measurement group_id="B3" value="75.0" lower_limit="67.0" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12</title>
        <description>The number of lesions is assessed at baseline (before treatment) and 12 weeks later.
The difference in lesions is recorded for each patient. The mean of disappeared lesions are then calculated for all patients.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daylight</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
Metvix®
Photodynamic Therapy Daylight: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
          </group>
          <group group_id="O2">
            <title>Conventional Treatment</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
Metvix®
Photodynamic Therapy Blue light: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12</title>
          <description>The number of lesions is assessed at baseline (before treatment) and 12 weeks later.
The difference in lesions is recorded for each patient. The mean of disappeared lesions are then calculated for all patients.</description>
          <units>number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="6.0"/>
                    <measurement group_id="O2" value="20.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Main analysis:
nbDPKAdispM3 the number of KA disappeared at M3 after treatment with DPDT compared to the inclusion layer,
nbCPKAdispM3 the number of KA disappeared at M3 after treatment with conventional blue light,
The primary endpoint is:
differenceM3 = nbDPKAdispM3 - nbCPKAdispM3 The main analysis will consist of a signed Wilcoxon rank test for matched data testing whether &quot;difference M3&quot; is significantly different from 0</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8460</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assesment</title>
        <description>Pain assesment with a VAS Pain scale
Visual analog scale [VAS] is a continuous scale comprised of a horizontal scale of 10 cm length . The scale is anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 10).</description>
        <time_frame>at inclusion (after treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daylight</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
Metvix®
Photodynamic Therapy Daylight: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
          </group>
          <group group_id="O2">
            <title>Conventional Treatment</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
Metvix®
Photodynamic Therapy Blue light: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assesment</title>
          <description>Pain assesment with a VAS Pain scale
Visual analog scale [VAS] is a continuous scale comprised of a horizontal scale of 10 cm length . The scale is anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 10).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.9"/>
                    <measurement group_id="O2" value="5.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesions Disappearance Rate at 1 Months From Baseline.</title>
        <description>The number of lesions is assessed at baseline (before treatment) and 1 month later.
The difference in lesions is recorded for each patient. The rate is the quotient: &quot; difference in lesions between baseline and at 1 month &quot;/nubmer of lesions at baseline</description>
        <time_frame>0(baseline),1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daylight</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
Metvix®
Photodynamic Therapy Daylight: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
          </group>
          <group group_id="O2">
            <title>Conventional Treatment</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
Metvix®
Photodynamic Therapy Blue light: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
          </group>
        </group_list>
        <measure>
          <title>Lesions Disappearance Rate at 1 Months From Baseline.</title>
          <description>The number of lesions is assessed at baseline (before treatment) and 1 month later.
The difference in lesions is recorded for each patient. The rate is the quotient: &quot; difference in lesions between baseline and at 1 month &quot;/nubmer of lesions at baseline</description>
          <units>percentage of disappeared lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" spread="7.2"/>
                    <measurement group_id="O2" value="94.6" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesions Disappearance Rate at 6 Months From Baseline.</title>
        <description>The number of lesions is assessed at baseline (before treatment) and 6 month later.
The difference in lesions is recorded for each patient. The rate is the quotient: &quot; difference in lesions between baseline and at 6 month &quot;/nubmer of lesions at baseline</description>
        <time_frame>0(baseline), 6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daylight</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
Metvix®
Photodynamic Therapy Daylight: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
          </group>
          <group group_id="O2">
            <title>Conventional Treatment</title>
            <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
Metvix®
Photodynamic Therapy Blue light: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
          </group>
        </group_list>
        <measure>
          <title>Lesions Disappearance Rate at 6 Months From Baseline.</title>
          <description>The number of lesions is assessed at baseline (before treatment) and 6 month later.
The difference in lesions is recorded for each patient. The rate is the quotient: &quot; difference in lesions between baseline and at 6 month &quot;/nubmer of lesions at baseline</description>
          <units>percentage of disappeared lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" spread="5.9"/>
                    <measurement group_id="O2" value="94.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>which adverse event data were collected over 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Daylight</title>
          <description>Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
Metvix®
Photodynamic Therapy Daylight: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug</description>
        </group>
        <group group_id="E2">
          <title>Conventional Treatment</title>
          <description>Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
Metvix®
Photodynamic Therapy Blue light: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>CHU de Limoges</organization>
      <phone>0555058616 ext +33</phone>
      <email>abdeslam.bentaleb@chu-limoges.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

